PharmaShots | Incisive News in 3 Shots

Subscribe Now

(ibrutinib)

Janssen's Imbruvica (ibrutinib) + Rituximab Receives the EC's Marketing Authorization for Previously Untreated Patients with Chronic Lymphocytic Leukemia

Janssen's Imbruvica (ibrutinib) + Rituximab Receives the EC's Marketing Authorization for Previously Untreated Patients with Chron...

September 8, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us